Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$155.38 -0.9%	$153.80	$140.68 ▼ $169.99	$377.32B	0.41	8.05 million shs	6.86 million shs
NVS Novartis	$119.66 -1.1%	$116.35	$96.06 ▼ $124.83	$255.69B	0.59	1.58 million shs	1.48 million shs
RHHBY Roche	$39.63 -1.6%	$40.07	$34.10 ▼ $44.31	$256.90B	0.45	1.13 million shs	891,572 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.98%	-0.24%	-0.97%	+0.93%	+4.12%
NVS Novartis	-1.15%	-1.75%	+0.27%	+9.12%	+8.46%
RHHBY Roche	-1.61%	-1.15%	-4.09%	+2.72%	+10.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JNJ Johnson & Johnson	4.9392 of 5 stars	3.3	4.0	4.2	3.9	3.5	1.7	1.9
NVS Novartis	1.5453 of 5 stars	1.0	3.0	2.5	0.0	2.7	0.0	1.9
RHHBY Roche	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.55	Moderate Buy	$171.00	10.05% Upside
NVS Novartis	2.00	Hold	$123.67	3.34% Upside
RHHBY Roche	2.57	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest JNJ, RHHBY, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$169.00 ➝ $171.00
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
5/13/2025	JNJ Johnson & Johnson	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00
4/28/2025	RHHBY Roche	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/28/2025	RHHBY Roche	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/24/2025	JNJ Johnson & Johnson	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/17/2025	JNJ Johnson & Johnson	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$166.00 ➝ $165.00
4/16/2025	JNJ Johnson & Johnson	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
4/16/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$88.82B	4.21	$13.00 per share	11.95	$29.69 per share	5.23
NVS Novartis	$53.22B	4.75	$10.58 per share	11.31	$21.59 per share	5.54
RHHBY Roche	$68.73B	3.68	$3.24 per share	12.22	$6.44 per share	6.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$14.07B	$8.99	17.28	14.04	2.14	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	18.70	13.58	1.64	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
RHHBY Roche	$9.40B	N/A	0.00	13.21	3.10	N/A	N/A	N/A	7/24/2025 (Estimated)

Latest JNJ, RHHBY, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.20	3.35%	N/A	57.84%	64 Years
NVS Novartis	$2.59	2.16%	N/A	40.47%	N/A
RHHBY Roche	$0.87	2.20%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.49	1.26	1.03
NVS Novartis	0.56	0.79	0.61
RHHBY Roche	0.85	1.48	1.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
NVS Novartis	13.12%
RHHBY Roche	N/A

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
NVS Novartis	0.01%
RHHBY Roche	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
RHHBY Roche	103,249	6.38 billion	N/A	Not Optionable

JNJ, RHHBY, and NVS Headlines

Recent News About These Companies

Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Moderate Buy" from Analysts

July 12, 2025 | americanbankingnews.com

Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 12, 2025 | marketbeat.com

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

July 11, 2025 | theglobeandmail.com

Smart Money Going in Senior Health: Key Stocks in Elderly Care

July 11, 2025 | zacks.com

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

July 10, 2025 | zacks.com

Roche Holding AG (OTCMKTS:RHHBY) Shares Bought by Moloney Securities Asset Management LLC

July 9, 2025 | marketbeat.com

RHHBY - Roche Holding AG ADR Sustainability - Morningstar

July 8, 2025 | morningstar.comM

RHHBY - Roche Holding AG ADR Chart - Morningstar

July 3, 2025 | morningstar.comM

Changes to the Roche Enlarged Corporate Executive Committee

June 30, 2025 | globenewswire.com

RHHBY - Roche Holding AG ADR Trailing Returns - Morningstar

June 27, 2025 | morningstar.comM

RHHBY Roche Holding AG - Seeking Alpha

June 27, 2025 | seekingalpha.com

RHHBY - Roche Holding AG ADR Key Metrics - Morningstar

June 25, 2025 | morningstar.comM

RHHBY - Roche Holding AG ADR Dividends - Morningstar

June 24, 2025 | morningstar.comM

Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript

June 23, 2025 | seekingalpha.com

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

June 23, 2025 | uk.finance.yahoo.com

Altrius Capital Management Inc Acquires 6,545 Shares of Roche Holding AG (OTCMKTS:RHHBY)

June 22, 2025 | marketbeat.com

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

June 20, 2025 | uk.finance.yahoo.com

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025 | finance.yahoo.com

Roche's Genentech reports positive results from lymphoma trial

June 20, 2025 | msn.com

Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

June 20, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/20/3102847/0/en/roche-s-lunsumio-and-polivy-combination-significantly-prolongs-remission-for-people-with-relapsed-or-refractory-large-b-cell-lymphoma.html$

Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025 | businesswire.com $https://www.businesswire.com/news/home/20250620976164/en/genentech%e2%80%99s-lunsumio-and-polivy-combination-significantly-prolongs-remission-for-people-with-relapsed-or-refractory-large-b-cell-lymphoma/$

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ, RHHBY, and NVS Company Descriptions

Johnson & Johnson NYSE:JNJ

$155.38 -1.44 (-0.92%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$155.98 +0.59 (+0.38%)

As of 04:02 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novartis NYSE:NVS

$119.66 -1.38 (-1.14%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$118.80 -0.86 (-0.72%)

As of 04:00 AM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Roche OTCMKTS:RHHBY

$39.63 -0.65 (-1.61%)

As of 07/15/2025 03:59 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time